Matthias Festag

A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development

Sally Robinson, Jean‐Luc Delongeas, Elizabeth Donald et al. · Regulatory Toxicology and Pharmacology · 2007 · 105 citations

Pharmacy, Pharmacology, Toxicology +17

A global pharmaceutical company initiative: An evidence-based approach to define the upper limit of body weight loss in short term toxicity studies

Kathryn Chapman, Fiona Sewell, Linda Allais et al. · Regulatory Toxicology and Pharmacology · 2013 · 70 citations · Full text

Pharmacy, Pharmacology, Toxicology +17

Pediatric Safety of Polysorbates in Drug Formulations

Christina Kriegel, Matthias Festag, Ravuri S. K. Kishore et al. · Children · 2019 · 64 citations · Full text

Pharmacy, Pediatrics, Pharmacology +17

An in vitro embryotoxicity assay based on the disturbance of the differentiation of murine embryonic stem cells into endothelial cells. II. Testing of compounds

Matthias Festag, Bruno Viertel, Pablo Steinberg et al. · Toxicology in Vitro · 2007 · 58 citations

Life Sciences, Developmental Biology, Toxicology +16

Characterization of a re‐engineered, mesothelin‐targeted<i>Pseudomonas</i>exotoxin fusion protein for lung cancer therapy

Frieder Bauss, Martin Lechmann, Ben‐Fillippo Krippendorff et al. · Molecular Oncology · 2016 · 56 citations · Full text

Medicine, Oncology, Pharmacology +15